1.86BMarket Cap
LossP/E TTM
Key Figures
41.100Open
41.105High
814.72KVolume
LossP/E TTM
23.29P/E Dynamic
--Dividend TTM
1.74%Turnover Ratio
41.090Prev. Close
38.010Low
23.31MTurnover
LossP/E Static
-15.50P/B
0.00%Div Yield TTM
-53.15%ROA
32.37052wk High
1.44Volume Ratio
-126.87MNet Profit
46.78MShares
-2.7353EPS TTM
1.61Beta
--ROE
3.60552wk Low
7.53%Amplitude
91.88%Gross Margin
1.86BMarket Cap
2.36Reward/Risk
4.16%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Urogen Pharma Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 41.12.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Urogen Pharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Urogen Pharma Ltd Highlights
StrengthsRisks
Urogen Pharma Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Urogen Pharma Ltd Info
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Ticker SymbolURGN
CompanyUrogen Pharma Ltd
CEOBarrett (Elizabeth A)
Websitehttps://www.urogen.com/
Shareholders
FAQs
What is the current price of Urogen Pharma Ltd (URGN)?
The current price of Urogen Pharma Ltd (URGN) is 38.24.
What is the symbol of Urogen Pharma Ltd?
The ticker symbol of Urogen Pharma Ltd is URGN.
What is the 52-week high of Urogen Pharma Ltd?
The 52-week high of Urogen Pharma Ltd is 32.37.
What is the 52-week low of Urogen Pharma Ltd?
The 52-week low of Urogen Pharma Ltd is 3.60.
What is the market capitalization of Urogen Pharma Ltd?
The market capitalization of Urogen Pharma Ltd is 1.79B.
Is Urogen Pharma Ltd (URGN) currently rated as Buy, Hold, or Sell?
According to analysts, Urogen Pharma Ltd (URGN) has an overall rating of Buy, with a price target of 41.12.
What is the Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN)?
The Earnings Per Share (EPS TTM) of Urogen Pharma Ltd (URGN) is -3.19.
